Oxygen Biotherapeutics to Present at FSX Investment Conference in Fort
Lauderdale on July 25th, 2013
Company to Conduct Additional Investor Meetings in Tampa, Sarasota, Naples,
West Palm Beach and Boca Raton
FSX Interlinked Investment Conference 2013
MORRISVILLE, N.C. -- July 23, 2013
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying
therapeutics, will present to an audience of principals and key decision
makers of broker/dealers and financial firms at the FSX Investment Conference
to be held at the Ritz Carlton in Fort Lauderdale, Florida from July
25th-27th, 2013. The Company’s interim CEO, President, and CFO Michael Jebsen
will present to the FSX audience at 2:15 pm on Thursday, July 25^th.
OXBT’s presentation at FSX coincides with several significant developments.
The Company recently initiated its second cohort of its Phase IIb clinical
trials being conducted in Israel and Switzerland to investigate the safety and
tolerability of Oxycyte® in patients with severe, non-penetrating traumatic
brain injury. Oxycyte® is a proprietary perfluorocarbon (PFC) emulsion is
designed to rapidly deliver oxygen to damaged tissues using small molecule
PFCs that can carry up to 4x more O2 and can dissolve the gases twice as fast
as normal blood cells. Also, the Company recently reported successful
completion of FDA requested immunocompetency studies on Oxycyte® and their
plan to submit the results from these safety studies to the FDA sometime this
month (July). This preclinical research program is fully-funded by the U.S.
Army, and the Company has entered into four additional Cooperative Research
and Development Agreements with the U.S. Navy to examine potential therapeutic
applications for Oxycyte®. These studies are either completed, underway or
being planned for decompression sickness (DCS) and spinal cord injury related
to DCS, TBI, hemorrhagic shock, and other wounds.
Mr. Jebsen will also be conducting additional meetings with investors in
Florida including Tampa, Naples, and Sarasota on Wednesday July 24^th and in
West Palm Beach, Boca Raton, and Fort Lauderdale on Thursday, July 25th.
Investors interested in 1-on-1 meetings should contact Robert Haag at
The Company’s investor presentation will include:
*An overview of the Company's business model
*A summary of progress with the FDA and Phase 2b testing in Israel and
*An update of current scientific results and indications of Oxycyte®
*A review of its current portfolio of products and applications
*Plans for increasing existing sources of revenue & funding, and an outline
for its growth trajectory
*Profiles of its management team and advisors
FSX is the premier investment conference organization in the United States.
Founded in 1983, FSX is a national organization comprised of independent FINRA
broker/dealer firms. Through a series of regularly scheduled investment
conferences, FSX brings these firms together with the purpose of sharing
information and showcasing investment opportunities. More information can be
found at http://www.fsxinterlinked.com/.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical products that efficiently
deliver oxygen to tissues in the body. The company has developed a proprietary
perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is
currently in clinical and preclinical studies for intravenous delivery for
indications such as traumatic brain injury, decompression sickness and stroke.
The company is also developing PFC-based creams and gels for topical delivery
to the skin for dermatologic conditions and potentially wound care. In
addition, the Company has commercialized its Dermacyte® line of skin care
cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor
Cosmetics of Switzerland.
This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. The forward-looking statements are subject to a
number of risks and uncertainties delays in new product introductions and
customer acceptance of these new products, and other risks and uncertainties
as described in our filings with the Securities and Exchange Commission,
including in our annual report on Form 10-K filed on June 26, 2013, as well as
other filings with the SEC. The company disclaims any intent or obligation to
update these forward-looking statements beyond the date of this release. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Robert Haag, 877-368-3566
Press spacebar to pause and continue. Press esc to stop.